Hoth Therapeutics Inc (NASDAQ: HOTH) is a patient-centric biopharma corporation that recently announced that it started preclinical trials for its HT-ALZ product. The study’s main goal is to find out HT-ALZ effects on pathological and behavioral markers of Alzheimer’s. The trial is also looking to determine whether HT-ALZ can help improve both memory and learning animals with Alzheimer’s. This study will also show if there’s an improvement in behavior when HT-ALZ blocks NK-IRs.
To analyze other forms of memory, the team of researchers will also see if chronic HT-ALZ therapies can impact non-spatial memory functions using novel object location tasks and novel object recognition. These tests will give the team the ability to evaluate both non-hippocampal and hippocampal-dependent memory. In addition, these tests don’t need water or food deprivation to help motivate the animal subjects, which can sometimes interfere with dosing regulation and drug delivery over time.
These preclinical trials are being conducted under the Scientific Research Agreement the Company entered into in June 2021.
What Hoth is all About
Hoth Therapeutics is a biopharma corporation that concentrates on the development of next-gen therapeutics for unmet medical requirements. The company’s pipeline development efforts concentrate on improving the lives of individuals suffering from some of these indications, including mast-cell-derived cancer, acne, asthma, psoriasis, chronic wounds, cancer therapy, and pneumonia. The company has also made two separate agreements to further develop therapeutic medical prospects that can be used to treat and prevent COVID-19.
One of Hoth’s Scientific Advisors, Glenn Cruse said that currents therapies for treating mast cell cancer typically target the signaling receptor covered by the c-KIT genome. The efficacy of current treatments can be negatively impacted by the c-KIT gene linked to disease development. She confirmed further that they were going to target the gene itself, no matter the mutation. She said that targeting the gene will help drive progression, allowing them to target the disease directly.
